Date of Award
The primary objectives of this interdisciplinary study were the synthesis of novel heterocyclic arylidenes and the investigation of their anticancer activity against U87 glioblastoma cell viability. Recently, novel hybrid derivatives have been considered as potential candidates for treating glioblastoma, demonstrating a synergistic anticancer effect in previous studies. 12 heterocyclic arylidenes with various functional groups, including halogens and boronic acid, were produced via a Knoevenagel condensation. These compounds and their starting reagents were then administered to U87 glioblastoma cancer cells at graded concentrations within a 12-well cell viability assay to determine each compound’s lethal concentration 50 (LC50). The LC50 of each compound was then compared to determine the effects of substituent type and position on anticancer activity. Although these arylidenes displayed some anticancer effects, their high LC50 suggest they have no significant effect on U87 glioblastoma cell viability and proliferation.
Hiramoto, Benjamin H., "Novel Heterocyclic Arylidene Derivatives as Anticancer Agents Against U87 Human Glioblastoma" (2020). Honors Theses. 231.
Glioblastoma multiforme; Antineoplastic agents; Brain--Cancer; Arylidene
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Files over 3MB may be slow to open. For best results, right-click and select "save as..."